Clinical Utility of Elecsys Anti-SARS-CoV-2 S Assay in COVID-19 Vaccination: An Exploratory Analysis of the mRNA-1273 Phase 1 TrialCOVID-19 백신 접종에서 Elecsys Anti-SARS-CoV-2 S 어세이의 임상적 유용성: mRNA-1273 1상 시험의 탐색적 분석Clinical Trial Published on 2022-01-192022-09-11 Journal: Frontiers in Immunology [Category] 임상, 치료기술, [키워드] 2019-nCoV absence acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Anti-SARS-CoV-2 S antibody antibody levels automated baseline choice clinical clinical utility collected coronavirus correlated correlation COVID-19 Day detectable dose Elecsy ELISA ELISAs first vaccination geometric mean geometric mean concentration healthy heterogeneous humoral immune response increases in injection International international standard mRNA mRNA-1273 nanoluciferase neutralization test neutralization tests Neutralizing antibodies participant Participants Phase 1 phase 1 trial Protein pseudovirus neutralizing antibody pseudovirus neutralizing antibody assay quantification Quantitative quantitative serology RBD RBD ELISA RBD-specific antibodies RBD-specific antibody Receptor binding domain respiratory Result Roche S-2P Sample SARS-CoV-2 second vaccination Seroconversion seroconverted severe acute respiratory syndrome Coronavirus shown specific antibodies specificity Spike protein the Spike U/mL vaccination Vaccine vaccine-induced antibody response WHO [DOI] 10.3389/fimmu.2021.798117 PMC 바로가기 [Article Type] Clinical Trial
Kinetics and persistence of cellular and humoral immune responses to SARS‐CoV‐2 vaccine in healthcare workers with or without prior COVID‐19이전 COVID-19 유무에 관계없이 의료 종사자의 SARS-CoV-2 백신에 대한 세포 및 체액 면역 반응의 동역학 및 지속성Original Article Published on 2022-01-182022-09-10 Journal: Journal of Cellular and Molecular Medicine [Category] MERS, 변종, 진단, [키워드] antibody antibody levels baseline BNT162b2 BNT162b2 mRNA vaccine cellular cellular immune responses circulating viral variant conducted COVID‐19 death declining decrease descending diagnosed dose form healthcare worker Healthcare workers highest Hospitalization humoral immune response humoral responses IFN IFN‐γ IgA level IgA levels IgG antibodies immune response immune response post‐infection immune response post‐vaccination immune responses Infection Kinetics longitudinal study mRNA vaccine natural infection neutralization Neutralization assay Neutralizing activity Neutralizing antibodies new infections of BNT162b2 participant persistence preserved SARS‐CoV‐2 SARS‐CoV‐2 infection SARS‐CoV‐2 infection secretion significantly spike‐specific CD4+ T cell spike‐specific CD8+ T cell subject T‐cell the disease titre Vaccine vaccine dose Viral waning immunity [DOI] 10.1111/jcmm.17186 PMC 바로가기 [Article Type] Original Article
Antibody Response and Variant Cross-Neutralization After SARS-CoV-2 Breakthrough InfectionSARS-CoV-2 돌발 감염 후 항체 반응 및 변형 교차 중화Article Published on 2022-01-112022-09-11 Journal: JAMA [Category] 변종, 진단, [키워드] antibody antibody levels Breakthrough infection COVID-19 cross-neutralization Health care Health care worker neutralization response SARS-CoV-2 variant [DOI] 10.1001/jama.2021.22898 PMC 바로가기 [Article Type] Article
Dynamics of spike-and nucleocapsid specific immunity during long-term follow-up and vaccination of SARS-CoV-2 convalescentsSARS-CoV-2 회복기의 장기 추적 및 예방 접종 중 스파이크 및 뉴클레오캡시드 특이적 면역의 역학Article Published on 2022-01-102022-09-10 Journal: Nature Communications [Category] 진단, 치료법, [키워드] Anti-viral immunity antibody antibody levels Antibody titers Asymptomatic BNT162b2 BNT162b2 mRNA boost circulating convalescent convalescent individual convalescent individuals correlated Decline declined delayed response Dynamics follow-up period Frequency Immunity increase in individual Infection long-lasting Long-term follow-up mild SARS-CoV-2 infection mRNA naïve vaccinees neutralizing antibody titers nucleocapsid Outcomes research responded to vaccination SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2-specific T cells selective specific immunity spike strength T cell T cell response T cells vaccination viral infection virus-neutralizing antibody waning immunity [DOI] 10.1038/s41467-021-27649-y PMC 바로가기 [Article Type] Article
Persistence of Anti-SARS-CoV-2 Antibodies in Long Term Care Residents Over Seven Months After Two COVID-19 Outbreaks두 번의 COVID-19 발생 후 7개월 동안 장기 요양 시설 입소자의 항 SARS-CoV-2 항체 지속성Immunology Published on 2022-01-032022-09-11 Journal: Frontiers in Immunology [Category] MERS, 진단, 치료법, [키워드] 229E Analysis Anti-nucleocapsid antibodies anti-nucleocapsid antibody Anti-spike antibody antibody levels approved attack rate binding domain Canada Care carried changes in collected comparison COVID-19 COVID-19 outbreak cross reaction demonstrated evaluate finding Gradual HCoV HCoV-229E HCoV-HKU1 HCoV-NL63 HCoV-OC43 HKU1 human coronavirus human coronavirus (HCoV) humoral humoral immune response Humoral response humoral responses individual individuals Long long term Long term care facilities median MONITOR monitors Month multiplexed immunoassay NL63 nucleocapsid OC43 outbreak Outbreak investigation outbreak investigations Outbreaks over participant participated performed platform provided public health RBD reaction Receptor binding domain Reinfection resident SARS-CoV-2 serologic test serologic testing serologic tests serological serological survey Serological surveys seronegative seropositive seropositive individual serostatus serum serum sample serum samples Seven Spike protein Spike proteins statistical analyses statistically significant survey term the spike protein were used [DOI] 10.3389/fimmu.2021.775420 PMC 바로가기 [Article Type] Immunology
Evaluation of neutralizing antibodies after vaccine BNT162b2: Preliminary data백신 BNT162b2 후 중화 항체 평가: 예비 데이터Article Published on 2022-01-012022-09-11 Journal: Journal of Clinical Virology [Category] SARS, 진단, 치료기술, [키워드] acute respiratory syndrome age antibody antibody levels Antibody test appear beta-coronavirus binding BNT162b2 BNT162b2 mRNA BNT162b2 mRNA vaccine carried caused complex coronavirus disease Coronavirus disease 2019 declined detect DiaSorin evaluated female participants female subjects FIVE followed by healthcare humoral immune response IgG IgG antibodies IgG antibody immune immunisation Immunisation safety immunogenicity data increase in individuals infected with SARS-CoV-2 male participant male subject male subjects mean value Neutralizing antibodies neutralizing antibody no significant difference outbreak pandemic plateau reached Receptor binding domain reported respiratory SARS-CoV-2 second dose seronegative Serum level serum levels significant difference statistically significant Surveillance the mean the vaccine two subject Two subjects vaccination Vaccine were infected Wuhan Wuhan, China [DOI] 10.1016/j.jcv.2021.105057 PMC 바로가기 [Article Type] Article
Should a third booster dose be scheduled after two doses of CoronaVac? A single-center experienceCoronaVac 2회 투여 후 세 번째 추가 접종을 예약해야 합니까? 단일 센터 경험Article Published on 2022-01-012022-09-11 Journal: Journal of medical virology [Category] SARS, 진단, 치료법, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Administered age anti-SARS-CoV-2 Anti-spike antibody antibody levels approval booster booster dose Capital CoronaVac coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 determine dose Emergency use evaluate examined had no healthcare healthcare worker Healthcare workers Immunoglobulin Immunoglobulin G immunoglobulin G response Inactivated vaccine Infection intervals investigated men Ministry of Health much higher pandemic participant receiving respiratory SARS-CoV-2 second dose seroconversion rate seronegative severe acute respiratory syndrome Coronavirus single-center the vaccine Turkey vaccination Vaccine was performed were used women [DOI] 10.1002/jmv.27318 PMC 바로가기 [Article Type] Article
Determinants of early antibody responses to COVID-19 mRNA vaccines in a cohort of exposed and naïve healthcare workers노출되고 순진한 의료 종사자 집단에서 COVID-19 mRNA 백신에 대한 초기 항체 반응의 결정 요인Clinical Trial Published on 2022-01-012022-09-11 Journal: EBioMedicine [Category] 변종, 임상, 진단, 치료기술, 치료법, [키워드] 95% CI Adults adverse events Affect allergy Alpha Analysis analyzed antibody Antibody avidity antibody levels Antibody Response Antigen antigens avidity Barcelona Beta BNT162b2 brand center Cohort Comorbidities Comorbidity COVID-19 COVID-19 mRNA vaccine Daniel Data collection days post-infection decision determinant development dose Effectiveness Efficacy European evaluated expected Factor Gamma had no Health care Health care worker health care workers healthcare worker healthy individual heterogeneity IgA IgG IgG and IgM IgG level IgG levels Immunity indicate Infectious disease Infectious diseases Influenza Innovation maintenance manuscript Moderna mRNA mRNA vaccination mRNA vaccines mRNA-1273 naïve neutralization neutralization capacity neutralizing capacity nucleocapsid omicron Pfizer/BioNTech preparation Program reagent receiving recommendation respond response responsiveness robust SARS-CoV-2 SARS-CoV-2 spike Science second dose seropositive Severo Ochoa shown Single-dose smoking Spanish state Study design Support supported symptomatic systemic adverse effect systemic adverse effects technology the preparation union vaccination vaccine doses vaccinees variant variants variants of concern wild-type [DOI] 10.1016/j.ebiom.2021.103805 PMC 바로가기 [Article Type] Clinical Trial
Longitudinal SARS-CoV-2 mRNA Vaccine-Induced Humoral Immune Responses in Patients with Cancer암 환자의 세로 SARS-CoV-2 mRNA 백신 유도 체액 면역 반응Article Published on 2021-12-152022-09-11 Journal: Cancer research [Category] MERS, SARS, 진단, 치료법, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Anti-spike antibody antibody levels Antibody Response B-cell BNT162b2 booster booster vaccination booster vaccinations Breakthrough infection breakthrough infections Cancer clinical care coronavirus COVID-19 illness dose elicit evaluated Follow-up Frequency hematologic humoral responses Immune checkpoint inhibitor Immune checkpoint inhibitors immune responses immunogenicity Immunoglobulin implication longitudinal Longitudinal studies malignancies median mRNA mRNA-1273 Patient patient selection patients Patients with cancer peak levels Population prospective cohort study receiving reduced remained respiratory response SARS-CoV-2 SARS-CoV-2 vaccine SARS-CoV-2 vaccines sequence severe acute respiratory syndrome Coronavirus severe COVID-19 illness Solid solid tumor solid tumors sustained therapeutic trajectory Treatment Tumor tumors vaccination Vaccinations Vaccine vaccine-induced immune response Variation [DOI] 10.1158/0008-5472.CAN-21-3554 PMC 바로가기 [Article Type] Article
Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England영국에서 연장된 COVID-19 백신 일정에 대한 혈청학적 반응 및 백신 효과Article Published on 2021-12-102022-09-12 Journal: Nature Communications [Category] 임상, 진단, [키워드] antibody antibody levels Antibody titer AstraZeneca AZD1222 BNT162b2 Cohort COVID-19 COVID-19 vaccine dose doses Effectiveness England estimate evaluate first dose Health policy Infection intervals magnitude National of BNT162b2 participant Pfizer Pfizer/BioNTech public health recipient response SARS-CoV-2 serological response vaccination Vaccine Vaccines [DOI] 10.1038/s41467-021-27410-5 PMC 바로가기 [Article Type] Article